Alpha Cognition Inc の最大収益セグメントは Pharmaceutical Treatments for Neurological Diseases で、最新の利益発表における収益は 10,220,275 です。地域別に見ると、United States が Alpha Cognition Inc の主要市場であり、収益は 6,792,024 です。
Alpha Cognition Incは収益を上げていますか?
いいえ、最新の財務諸表によると、Alpha Cognition Incの純損失は$0です。
Alpha Cognition Incに負債はありますか?
いいえ、Alpha Cognition Incの負債は0です。
Alpha Cognition Incの発行済株式数は何株ですか?
Alpha Cognition Incの総発行済株式数は0株です。
主要データ
前終値
$5.68
始値
$5.88
当日レンジ
$5.71 - $5.98
52週レンジ
$4.5 - $11.54
取引高
45.2K
平均取引高
62.5K
配当利回り
--
1株当たり利益(TTM)
-1.17
時価総額
$126.3M
ACOGとは何ですか?
Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The firm's ZUNVEYL (benzgalantamine) product is a delayed release oral tablet formulation indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. Its pre-clinical development programs include ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mTBI; ALPHA-0602; ALPHA-0702 & ALPHA-0802 (Progranulin and Progranulin GEM’s) for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis or Lou Gehrig’s disease and spinal muscular atrophy, and ALPHA-1062 for the treatment of acute pancreatitis.